[go: up one dir, main page]

AU2001247233A1 - Ppar gamma agonists for the treatment of liver inflammatory disorders - Google Patents

Ppar gamma agonists for the treatment of liver inflammatory disorders

Info

Publication number
AU2001247233A1
AU2001247233A1 AU2001247233A AU4723301A AU2001247233A1 AU 2001247233 A1 AU2001247233 A1 AU 2001247233A1 AU 2001247233 A AU2001247233 A AU 2001247233A AU 4723301 A AU4723301 A AU 4723301A AU 2001247233 A1 AU2001247233 A1 AU 2001247233A1
Authority
AU
Australia
Prior art keywords
treatment
inflammatory disorders
ppar gamma
gamma agonists
liver inflammatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001247233A
Inventor
Roger A. Davis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
San Diego State University
Original Assignee
San Diego State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by San Diego State University filed Critical San Diego State University
Publication of AU2001247233A1 publication Critical patent/AU2001247233A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2001247233A 2000-02-24 2001-02-23 Ppar gamma agonists for the treatment of liver inflammatory disorders Abandoned AU2001247233A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US18459200P 2000-02-24 2000-02-24
US60/184,592 2000-02-24
US18732100P 2000-03-06 2000-03-06
US60/187,321 2000-03-06
PCT/US2001/006101 WO2001062238A2 (en) 2000-02-24 2001-02-23 Ppar gamma agonists for the treatment of liver inflammatory disorders

Publications (1)

Publication Number Publication Date
AU2001247233A1 true AU2001247233A1 (en) 2001-09-03

Family

ID=26880294

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001247233A Abandoned AU2001247233A1 (en) 2000-02-24 2001-02-23 Ppar gamma agonists for the treatment of liver inflammatory disorders

Country Status (3)

Country Link
US (1) US20020006942A1 (en)
AU (1) AU2001247233A1 (en)
WO (1) WO2001062238A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1647289A1 (en) * 2001-02-27 2006-04-19 Medtronic Vascular, Inc. Peroxisome proliferator-activated receptor gamma ligand eluting medical device
US20020127263A1 (en) * 2001-02-27 2002-09-12 Wenda Carlyle Peroxisome proliferator-acitvated receptor gamma ligand eluting medical device
US20030220374A1 (en) * 2002-01-14 2003-11-27 Pharmacia Corporation Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
DE10237571A1 (en) * 2002-08-13 2004-02-26 Biotronik Meß- und Therapiegeräte GmbH & Co. Ingenieurbüro Berlin Endovascular implant with active coating
ITFI20030058A1 (en) * 2003-03-06 2004-09-07 Univ Firenze PHARMACEUTICAL FORMULATIONS CONTAINING THIAZOLIDINEDIONI
US20160331729A9 (en) 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
EP3788877B1 (en) * 2007-04-11 2024-08-07 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
WO2010105103A1 (en) 2009-03-11 2010-09-16 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
CN107441089A (en) * 2017-08-14 2017-12-08 合肥工业大学 A kind of new application of row ketone medicine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925657A (en) * 1997-06-18 1999-07-20 The General Hospital Corporation Use of PPARγ agonists for inhibition of inflammatory cytokine production
AU8747998A (en) * 1997-08-21 1999-03-16 Takeda Chemical Industries Ltd. Anti-inflammatory agent
ES2259459T3 (en) * 1997-11-19 2006-10-01 Takeda Pharmaceutical Company Limited NEW APOPTOSIS INHIBITORS.
US6028088A (en) * 1998-10-30 2000-02-22 The University Of Mississippi Flavonoid derivatives

Also Published As

Publication number Publication date
WO2001062238A9 (en) 2003-01-09
WO2001062238A2 (en) 2001-08-30
US20020006942A1 (en) 2002-01-17
WO2001062238A3 (en) 2002-08-29

Similar Documents

Publication Publication Date Title
ZA200401004B (en) Combination for the treatment of inflammatory disorders
IL155093A0 (en) Morpholin-acetamide derivatives for the treatment on inflammatory diseases
PL351134A1 (en) Compositions for treatment of disorders of the oesophagus
IL162485A0 (en) Compounds for the treatment of inflammatory disorders
AU2003213787A1 (en) Compositions and methods for the treatment of anorectal disorders
AU2001272852A1 (en) Composition for the treatment of migraine
AU2003286728A1 (en) Compounds for the treatment of metabolic disorders
AU2002233928A1 (en) Cycloalkylfused (g)-indole compounds as spla2-inhibitors in the treatment of inflammatory diseases
AU2001247233A1 (en) Ppar gamma agonists for the treatment of liver inflammatory disorders
AU2001267404A1 (en) Novel compounds for the treatment of inflammatory and cardiovascular diseases
SI1200114T1 (en) Ppar delta inhibitors for the treatment of cardiovascular diseases
AU2002258798A1 (en) Methods for the treatment of hepatic disorders
AU2001291172A1 (en) Methods for the diagnosis of neoplastic disorders using angiogenin
AU2939000A (en) Preventive or therapeutic agents for inflammatory dermatoses
NO20012612D0 (en) Isonipecotamides for the treatment of integrin-mediated disorders
AU2002339673A1 (en) Agonists and antagonists of ryzn for the treatment of metabolic disorders
AU2002221566A1 (en) Novel benzimidazole derivatives for the treatment of gaba-alpha mediated disorders
TR199902015A3 (en) The use of aryl-cyclohexylamine derivatives against CNS disorders.
AU2003239967A1 (en) Compound for the treatment of cns disorders
AU2003243214A1 (en) Salts of bis-arylsulfones for the treatment of cns disorders
AU2003240174A1 (en) Compositions for the treatment of edematous-firbrosclerotic panniculopathy
AU2002303162A1 (en) Il-1ss inhibition for myeloma and related disorders
HK1064662A (en) Compounds for the treatment of inflammatory disorders
AU2003232844A1 (en) Morpholin-acetamide derivatives for the treatment of inflammatory diseases
AU2002339680A1 (en) Agonists and antagonists of bromix for the treatment of metabolic disorders